# InterVene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intervene

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.intervene-med.com
- Total disclosed funding: $32M
- Latest round: Series A (Oct 7, 2024)
- Investors on record: 8

## About

InterVene, Inc. is a medical technology company focused on developing innovative interventional devices for treating chronic venous insufficiency and related conditions, enhancing patient care through advanced solutions.Founded in 2011 and headquartered in San Francisco, US, InterVene, Inc. specializes in creating medical devices to address chronic venous conditions. The company was co-founded by Fletcher Wilson and is currently led by CEO Jeff Elkins. InterVene has successfully raised a total of USD 13.00 mn through its Series A funding round in October 2024, co-led by RiverVest Ventures and Treo Ventures. The latest funding coincides with their goal to enhance their flagship product while advancing clinical investigations in the U.S.InterVene Inc. specializes in the development and manufacturing of advanced interventional devices aimed at treating chronic venous insufficiency (CVI) and post-thrombotic venous obstructions. Their flagship product, the Recana™ device, is engineered to efficiently de-bulk and recanalize chronic venous occlusions resulting from conditions such as deep vein thrombosis (DVT). The Recana™ device offers a novel approach to addressing the complications of CVI, which can lead to severe symptoms such as leg swelling, pain, and skin changes. InterVene's primary customer base includes healthcare facilities, vascular surgeons, and interventional specialists across the United States, where the product is currently undergoing clinical investigations. While the company is focused on the U.S. market for its investigational device, it aims to expand its reach into other regions as further developments and regulatory approvals are obtained.InterVene Inc. operates on a business-to-business (B2B) model, primarily engaging with hospitals and surgical centers that require innovative solutions for managing chronic venous conditions. The revenue structure revolves around sales of their Recana™ device, available through direct partnerships with medical facilities and distributors. Each transaction involves procurement agreements whereby healthcare providers acquire the devices for clinical use, thereby enhancing patient outcomes. Given the investigational status of the Recana™ device, pricing structures and specific financial agreements are tailored to align with the regulatory landscape and the development phase.In October 2024, InterVene, Inc. raised USD 13 mn in Series A funding to advance their initiatives. The company plans to utilize these funds for the final development of the Recana catheter system, initiation of clinical cases, regulatory submission, and market clearance in the United States, alongside initial commercialization and post-market clinical research. As part of their growth strategy, InterVene intends to expand its operations into new geographic regions following regulatory approvals, solidifying its market presence in areas with high demand for chronic venous treatments.

## Funding rounds

- Series A, Oct 7, 2024, $13M — RiverVest Ventures Partners, Treo Ventures
- Series B, May 13, 2019, $13M — RiverVest Ventures Partners, Boston Scientific, Correlation Ventures, 503 Partners
- Series A, Mar 23, 2015, $5.9M — Boston Scientific, LaunchCapital, Green Park & Golf Ventures, North Texas Angels Network

## Investors

- Boston Scientific — Series A, Series B
- LaunchCapital (https://capitalatlas.ai/funds/launchcapital) — Series A
- Green Park & Golf Ventures (https://capitalatlas.ai/funds/green-park-golf-ventures) — Series A
- North Texas Angels Network — Series A
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B, Series A
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series B
- 503 Partners (https://capitalatlas.ai/funds/503-partners) — Series B
- Treo Ventures (https://capitalatlas.ai/funds/treo-ventures) — Series A